



Editorial

What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?

The burden of isoniazid-resistant tuberculosis (Hr-TB) and multidrug- and/or rifampicin mono-resistant tuberculosis (MDR/RR-TB) is increasing worldwide, and the high TB burden countries are the worst affected^{1,2}. Ideally, early identification and treatment of Hr-TB is important to prevent progression to MDR-TB, poly-drug resistant (DR) TB, extensively drug-resistant (XDR) TB and worse treatment outcomes³. The term XDR-TB will likely need to be re-defined in view of the injectables no longer being recommended as the frontline treatment for MDR-TB⁴. Although both solid and liquid culture methods are invaluable tools for the laboratory diagnosis of DR-TB, they are time-consuming to detect drug resistance and drug susceptibility. Rapid molecular methods such as GeneXpert and/or first-and second-line line probe assay (SL-LPA), when performed in tandem, can provide valuable information about early diagnosis and drug susceptibility testing (DST)-guided treatment of DR-TB^{3,5}. In this context, it is also essential to offer universal DST to all TB patients at baseline and during follow up. For this, national TB control programmes must have adequate laboratory infrastructure, trained healthcare workers and quality-assured laboratory DST reporting for both first-and second-line drugs to facilitate DST-guided treatment. As annual national DR-TB surveys are time-consuming and expensive, national surveys should be carried out periodically to ascertain trends in DR-TB.

The WHO recommends, albeit based on weak evidence, substitution of isoniazid with levofloxacin (Lfx) for the treatment of laboratory-confirmed Hr-TB (rifampicin-susceptible) and use of the drug regimen consisting of ERZ (ethambutol, rifampicin, pyrazinamide)-Lfx for a duration of six months without a split of intensive and continuation phases⁶.

It further advises against the addition of streptomycin or any other injectable agent in the regimen. Treatment may be extended up to nine months depending upon the clinical, radiological and microbiological response and especially in extrapulmonary TB involving bone, brain/meninges and/or miliary TB. Substitution of a drug in case of additional drug resistance or intolerance can be effected by, in order of preference with linezolid (Lzd), clofazimine (Cfz) or cycloserine (Cs). High-dose isoniazid (15-20 mg/kg/day) may not be useful in Indian patients with Hr-TB since the *katG* gene mutation conferring high-dose INH resistance is present in >90 per cent of isolates⁷. According to the first National Anti-Tuberculosis Drug Resistance Survey (NDRS) in India, resistance to any fluoroquinolone (FQ) was found in about eight per cent of Hr-TB and resistance to Lzd was uncommon in MDR/RR-TB and even less in H mono/poly-DR-TB (personal communication with RNTCP). Cultures should be done at the end of 2-3 months and thereafter as appropriate⁸.

Although Mfx may arguably be more potent than Lfx⁹, the main advantage of the latter is less QTcF prolongation, which has obvious advantages when combined with other QTcF-prolonging agents, such as bedaquiline (Bdq) and Cfz in regimen. Peak plasma concentration and exposure to Mfx significantly decreases with concurrent administration of rifampicin⁹; this is another advantage of using Lfx, which does not require dosage adjustment. Unlike Mfx, Lfx requires dose modification in patients with advanced stages of chronic kidney disease (CKD).

The recently published consolidated guidelines on MDR/RR-TB⁹ are based on evidence synthesized from a recently completed Phase III clinical trial of delamanid (Dlm)^{10,11}, an individual patient data

This editorial is published on the occasion of World Tuberculosis Day - March 24, 2019

meta-analysis (IPD-MA) of longer¹² and 9-12-month shorter MDR-TB regimens^{13,14} and efficacy and pharmacokinetic data from Dlm and Bdq-related clinical trials¹⁵. There are no changes in the timing of antiretroviral drugs administration in people living with HIV (PLHIV) with MDR/RR-TB, use of surgery and models of MDR-TB care (ambulatory care/hospitalization)¹⁶.

A new feature in the guidelines is that the second-line anti-TB drugs used for designing individualized MDR-TB regimens have been re-grouped into A, B and C and the drug ranking is based on their estimated efficacy profiles⁹. The group A drugs include FQ, Lfx or Mfx; Bdq and Lzd; group B includes Cfz and Cs or terizidone and group C contains ethambutol (E), Dlm, pyrazinamide, imipenem-cilastatin (Imp-Cln) or meropenem (Mpm), amikacin (Am) or streptomycin (S), ethionamide (Eto), or prothionamide and *p*-aminosalicylic acid (PAS). Lack of efficacy in the Dlm phase III study has resulted in its classification as a group C drug though this was based on a six-month culture conversion outcome^{10,11}.

While designing the individualized longer (18-20 month) MDR-TB regimen, a strong recommendation has been made to include all three drugs from group A, and to complete the regimen, the fourth drug should be from group B (and if it is not possible, then the fourth drug may be selected from the group C). A fully oral long-term regimen is the preferred option and the injectable agents, kanamycin and capreomycin, are no longer recommended because these were associated with higher treatment failure, relapse rates and mortality and toxicity⁹. The long-term Bdq-containing drug regimen should have at least four drugs for initial six months and subsequently three drugs to be continued for rest of the duration of treatment. Although the optimal number of drugs for the regimen is uncertain, we recommend a minimum of four but ideally five likely effective drugs¹². The individualized, longer MDR-TB regimen is to be administered for a total duration of 18-20 months, and the duration is primarily based on patient's response to treatment or 15-17 months after culture conversion. However, the optimal treatment duration remains unclear. The WHO recommendations have emphasized monthly sputum cultures along with smear microscopy⁹.

Pyrazinamide is to be used for MDR/RR-TB only when DST reveals susceptibility⁹ (though this is not readily available and is technically challenging).

Every dose of Imp-Cln or Mpm is administered with clavulanic acid (available only as amoxicillin clavulanic acid) and this combination is counted as single drug. In selected patients where a regimen cannot be constructed because of resistance profiles or drug-specific toxicity, Am or streptomycin is to be used only in patients >18 yr of age, and when high-quality audiometry monitoring for hearing loss is available. Am is to be substituted with streptomycin only if it is not available or some other contraindication exists, and when DST confirms susceptibility to streptomycin (phenotypic DST is required for streptomycin as molecular DST with SL-LPA does not detect it)⁹.

It should be noted that thiacetazone, gatifloxacin and high-dose isoniazid were not included in the IPD-MA for longer regimens because of an inadequate number of patients¹² (both gatifloxacin and thioacetazone are no longer available). Evidence on the safety and efficacy of the following drugs was insufficient for review: use of Bdq beyond six months and below the age of six years and Dlm use beyond six months and below the age of three years; concomitant use of Bdq and Dlm. It was observed that the use of Lzd for at least six months showed increased efficacy and using it for the entire duration would likely be better¹²; however, one needs to balance this against the high rates of drug toxicity with prolonged use.

The new WHO guidelines has left open the option of using the longer 18-20 month group A-based regimen or the standardized shorter MDR-TB regimen containing an injectable which is given for 9-11 months⁹. Which regimen should preferably be used? In the recently published STREAM trial, the shorter injectable containing 9-11 month regimen was found to be non-inferior to the conventional 18-20 month older WHO regimen (also contained an injectable)¹⁴. However, bacteriologic outcomes were worse with the shorter regimen and there was a trend to worse outcomes in HIV-infected persons in both arms. Given these considerations, the toxicity and tolerability profiles (including months of painful injections), our personal recommendation is that the longer pan-oral regimen is preferable and that the standardized shorter MDR-TB regimen containing an injectable should only be used as an exception (for example, if drugs are not readily accessible) and provided (*i*) there is no proven or likely resistance to any component of the regimen (except isoniazid), (*ii*) there is access to baseline and longitudinal monitoring for hearing loss, (*iii*) FQ and second line injectable

drug (SLID) resistance has been excluded, and (iv) patients have been counselled about the risks of this regimen and agree to receive it. There should be clear plans within the programme or provider setting to transition to an all-oral group A-based regimen because the shorter WHO injectable-based regimen is likely to be an inferior one from an efficacy and mortality point of view (though there are no head-to-head trials yet), and Am is toxic and associated with chronic painful injections driving poor adherence.

Active TB drug-safety monitoring and management (aDSM)¹⁷ should be an integral part of MDR-TB management as several drugs have additive toxicities. Bdq, Dlm, FQ (Mfx>Lfx) and Cfz have the potential to prolong QTcF. It is advised that deficiencies of potassium, calcium and magnesium should be corrected first, and if QTcF >500 ms persists, then the likely offending drug(s) should be stopped. Similarly, several drugs (Lzd, ethambutol and INH) in the regimen, when given in combination, can produce optic neuropathy¹⁷.

Lzd is a potent drug with potential toxicity when used on long-term basis in MDR-TB regimens¹⁸. Haematological toxicity occurs early, whereas peripheral and optic neuropathy occurs late¹⁸. Lactic acidosis is a rare complication. Pyridoxine (100 mg daily) can be administered to decrease the risk of haematological toxicity. Lzd is very rarely associated with serotonin syndrome when administered with selective serotonin re-uptake inhibitors and other medicines known to increase serotonin concentration in the central nervous system^{19,20}. In this specific context, patients should be instructed to avoid foods and liquids rich in tyramine concentration.

Proposed Indian recommendations for the fully oral longer regimen include five drugs in the intensive phase and four drugs in the continuation phase [Bdq(6 months) Lfx Lzd Cfz Cs]. After the drug procurement, implementation will start in a phased manner. If resistance to the FQ class is detected on the SL-LPA, then preferably two drugs (or at least one) from group C, e.g. Dlm and/or PAS, should be added to the regimen. In some cases high-dose Mfx (Mfx^h) could be useful provided there is no resistance to Mfx^h (1.0 µg)²¹ on LC-DST¹⁷ [though specific mutations of the SL-LPA, i.e. A90V, S91P, D94A (*gyrA*) suggest low level Mfx resistance in many settings]. Baseline SL-LPA should be performed for all patients with MDR/RR-TB to clarify whether there is additional FQ class resistance, which varies from 10 to 40 per cent in India (personal

communication with RNTCP). A fully oral Bdq-containing shorter regimen remains a good prospect for the treatment of MDR-TB in future.

Acknowledgment: The first author (SKS) is supported by the JC Bose National Fellowship (SB/S2/JCB-04/2013) of the Department of Science & Technology, Ministry of Science and Technology, Government of India, New Delhi. The second author (KD) is supported by the South African MRC (RFA-EMU-02-2017) and the EDCTP (TMA-2015SF-1043 & TMA-1051-TESSAI).

Conflicts of Interest: The first author (SKS) is a member of the National Technical Expert Group on treatment of TB, Revised National Tuberculosis Control Programme, Central TB Division, Ministry of Health & Family Welfare, Government of India. The second author declares no conflicts of interest.

Surendra K. Sharma^{1,2} & Keertan Dheda^{3,4*}

¹Department of Molecular Medicine, Jamia Hamdard Institute of Molecular Medicine, Jamia Hamdard (Deemed-to-be-University), New Delhi, ²Departments of General Medicine & Respiratory Medicine, Jawaharlal Nehru Medical College (JNMC), Datta Meghe Institute of Medical Science, Wardha, India, ³Department of Medicine & UCT Lung Institute, Division of Pulmonology, Centre for Lung Infection & Immunity, University of Cape Town, Cape Town, South Africa & ⁴Department of Immunology & Infection, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK

*For correspondence:
keertandheda@uct.ac.za

Received March 30, 2019

References

1. World Health Organization. *Global Tuberculosis Report 2018*. Geneva: WHO; 2018.
2. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, *et al*. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. *Lancet Respir Med* 2017. pii: S2213-2600(17)30079-6.
3. Pietersen E, Ignatius E, Streicher EM, Mastrapa B, Padanilam X, Pooran A, *et al*. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: A cohort study. *Lancet* 2014; 383 : 1230-9.
4. Reuter A, Tisile P, von Delft D, Cox H, Cox V, Ditiu L, *et al*. The devil we know: Is the use of injectable agents for the treatment of MDR-TB justified? *Int J Tuberc Lung Dis* 2017; 21 : 1114-26.
5. Central TB Division. *Guidelines on programmatic management of drug resistant TB (PMDT) in India*.

- Revised national tuberculosis control programme*. New Delhi: Directorate-General of Health Services, Ministry of Health & Family Welfare, Government of India; 2017. Available from: <https://tbcindia.gov.in/index1.php?lang=1&level=2&sublinkid=4781&lid=3306>, accessed on January 30, 2019.
6. World Health Organization. *WHO treatment guidelines for rifampicin- and multidrug-resistant tuberculosis*, 2018 update. Geneva: WHO; 2018. Available from: <https://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/gdg-meeting-mdr-rr-tb-treatment-2018-update/en/>, accessed on January 30, 2019.
 7. Chatterjee S, Poonawala H, Jain Y. Drug-resistant tuberculosis: Is India ready for the challenge? *BMJ Glob Health* 2018; 3 : e000971.
 8. Ministry of Health & Family Welfare, Government of India. *Report of the first national anti-tuberculosis drug resistance survey: India 2014-16*. Ministry of Health & Family Welfare, Government of India; 2018. Available from: <https://tbcindia.gov.in/showfile.php?lid=3315>, accessed on January 30, 2019.
 9. World Health Organization. *WHO consolidated guidelines on drug-resistant tuberculosis treatment*. Geneva: WHO; 2019.
 10. World Health Organization. *WHO position statement on the use of delamanid for multidrug-resistant tuberculosis*. Geneva: WHO; 2018. Available from: https://www.who.int/tb/publications/2018/Position_Paper_Delamanid/en/, accessed on January 30, 2019.
 11. von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, *et al*. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: A multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. *Lancet Respir Med* 2019; 7 : 249-59.
 12. Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF, Baghaei P; Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB Treatment-2017, *et al*. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: An individual patient data meta-analysis. *Lancet* 2018; 392 : 821-34.
 13. Ahmad Khan F, Salim MAH, du Cros P, Casas EC, Khamraev A, Sikhondze W, *et al*. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: Individual patient data and aggregate data meta-analyses. *Eur Respir J* 2017; 50 .pii: 1700061.
 14. Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, *et al*. A trial of a shorter regimen for rifampin-resistant tuberculosis. *N Engl J Med* 2019; 380 : 1201-13.
 15. Ionescu AM, Mpobela Agnarson A, Kambili C, Metz L, Kfoury J, Wang S, *et al*. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: A cost-effectiveness analysis. *Expert Rev Pharmacoecon Outcomes Res* 2018; 18 : 677-89.
 16. World Health Organization. *WHO treatment guidelines for drug-resistant tuberculosis: 2016 update*. Geneva: WHO; 2016.
 17. World Health Organization. *Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation*. Geneva: WHO; 2015. Available from: http://apps.who.int/iris/bitstream/10665/204465/1/WHO_HTM_TB_2015.28_eng.pdf, accessed on January 30, 2019.
 18. Olayanju O, Esmail A, Limberis J, Gina P, Dheda K. Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen. *Int J Infect Dis* 2019. pii: S1201-9712(19)30199-7.
 19. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. *Pharmacotherapy* 2007; 27 : 1189-97.
 20. Bernard L, Stern R, Lew D, Hoffmeyer P. Serotonin syndrome after concomitant treatment with linezolid and citalopram. *Clin Infect Dis* 2003; 36 : 1197.
 21. World Health Organization. *Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis*. Available from: <http://www.who.int/iris/handle/10665/275469>, accessed on January 30, 2019.